Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk-Reference-Cited by-同舟云学术

Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk

Published:2020-03-02 Issue:7 Volume:22 Page:1024-1034
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Schernthaner Guntram¹,Groop Per‐Henrik²³⁴,Kalra Philip A.⁵,Ronco Claudio⁶⁷,Taal Maarten W.⁸

Affiliation:

1. Department of Medicine IRudolfstitung Hospital Vienna Austria

2. Abdominal Center, NephrologyUniversity of Helsinki and Helsinki University Hospital Helsinki Finland

3. Folkhälsan Institute of GeneticsFolkhälsan Research Center, Biomedicum Helsinki Helsinki Finland

4. Department of Medicine, Central Clinical SchoolMonash University Melbourne Victoria Australia

5. Department of Renal MedicineSalford Royal Hospital Salford UK

6. Department of Medicine (DIMED)Università degli Studi di Padova Veneto Italy

7. Department of Nephrology, Dialysis & Transplantationand International Renal Research Institute (IRRIV), San Bortolo Hospital Vicenza Italy

8. Division of Medical Sciences and Graduate Entry MedicineUniversity of Nottingham Nottingham UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13994

Reference44 articles.

1. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

2. Food and Drug Administration (FDA). Guidance for industry diabetes mellitus‐evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008.https://www.fda.gov/media/71297/download. Accessed October 14 2019.

3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

4. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

5. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review;Kidney and Blood Pressure Research;2023

2. SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?;Polish Archives of Internal Medicine;2022-09-12

3. Proteomic analysis of mouse kidney tissue associates peroxisomal dysfunction with early diabetic kidney disease;2021-10-22

4. Caffeic Acid, One of the Major Phenolic Acids of the Medicinal Plant Antirhea borbonica, Reduces Renal Tubulointerstitial Fibrosis;Biomedicines;2021-03-30

5. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes;Diabetes Therapy;2020-09-29